Related Experiment Video
Updated: May 14, 2026
08:33
A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide
Published on: December 15, 2014
Cytokines in chronic respiratory diseases
Sergei P Atamas1, Svetlana P Chapoval, Achsah D Keegan
1Department of Medicine, University of Maryland School of Medicine Baltimore, MD 21201 USA ; Department of Microbiology and Immunology, University of Maryland School of Medicine Baltimore, MD 21201 USA ; Baltimore VA Medical Center Baltimore, MD 21201 USA.
F1000 Biology Reports
|February 16, 2013
Summary
Cytokines regulate lung immune responses, but dysregulation causes chronic diseases like asthma, COPD, and pulmonary fibrosis. Understanding these cytokine pathways offers therapeutic targets for lung repair and disease management.
Area of Science:
- Immunology
- Pulmonology
- Molecular Biology
Background:
- Cytokines are crucial for immune responses, tissue repair, and homeostasis in the lungs.
- Dysregulated cytokine production can lead to chronic inflammation, airway remodeling, and fibrosis.
- Asthma, COPD, and pulmonary fibrosis are major chronic lung diseases characterized by inflammatory processes.
Purpose of the Study:
- To elucidate the roles of specific cytokines in the pathology of asthma, COPD, and pulmonary fibrosis.
- To identify common molecular mechanisms underlying these chronic lung diseases.
- To explore potential therapeutic interventions targeting cytokine pathways.
Main Methods:
- Review and synthesis of existing literature on cytokines in chronic lung diseases.
- Analysis of molecular mechanisms driving pathology in asthma, COPD, and pulmonary fibrosis.
- Identification of overlapping inflammatory pathways and cytokine signaling.
Main Results:
- Detailed description of cytokine involvement in asthma, COPD, and pulmonary fibrosis.
- Highlighting shared molecular pathways contributing to disease progression.
- Identification of dysregulated cytokine production as a key pathological feature.
Conclusions:
- Cytokine dysregulation is a central mechanism in the pathogenesis of asthma, COPD, and pulmonary fibrosis.
- Overlapping molecular mechanisms present opportunities for novel therapeutic strategies.
- Targeting specific cytokine pathways could lead to improved treatment outcomes for chronic lung diseases.
Related Concept Videos
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...